← board
AYTU
Aytu BioPharma, Inc.distress 3/10 · well-funded / low risk$2.20+2%today-24% from 52w high
Lead: Vascular Ehlers-Danlos Syndrome
Revenue
$41M
Liquidity
$27M
Runway
13.8 yrs
Shares 1y
+8%
Price & events
-18.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.8%
1D
+1.8%
1W
-2.3%
1M
-12.7%
3M
-18.6%
6M
-16.4%
1Y
-20.9%
2Y
-97.3%
5Y
-98.2%
All
Overview
- Market Cap
- $23.60M
- Enterprise Value
- $6.44M
- Volume
- 351
- 52 Week Range
- $1.71 – $2.90
- Total Shares
- 10.73M
- Float Shares
- 7.63M
- Short %
- 3.78%
- % Held by Insiders
- 8.98%
- % Held by Institutions
- 36.77%
- RVOL
- 0.02x
- Beta
- 0.25
Pipeline stages · 1 programs
Enzastaurin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06 | Phase 3 | Enzastaurin | Vascular Ehlers-Danlos Syndrome | 260 | suspended |
Catalyst news & presentations · 3
- 2025-06-05partnershipEXXUA (gepirone) · Exclusive US commercialization agreement with Fabre-Kramer, including $6M upfront payments and tiered milestones/royalties.SEC 8-K
- 2024-10-01partnershipAdzenys XR-ODT, Cotempla XR-ODT · Exclusive agreement with Lupin Pharma Canada Ltd to commercialize in CanadaSEC 8-K
- 2024-08-06partnershipSale of consumer health businessSEC 8-K
Approved drugs (4)
- KARBINAL ERCARBINOXAMINE MALEATE2013 · Prescription
- ACIPHEX SPRINKLERABEPRAZOLE SODIUM2013 · Discontinued
- ZOLPIMISTZOLPIDEM TARTRATE2008 · Discontinued
- METADATE CDMETHYLPHENIDATE HYDROCHLORIDE2001 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+332% upside) · 3 analysts
- 2026-06-11Ascendiant CapitalBuy
- 2025-12-10Ascendiant CapitalBuy
- 2025-09-25Maxim GroupBuy
- 2025-09-25Ascendiant CapitalBuy
- 2025-07-01Lake StreetBuy
- 2025-06-30Ascendiant CapitalBuy
Competitors — Vascular Ehlers-Danlos Syndrome
- none identified
Recent news
- 2026-07-08AYTU Q2 2026 Earnings: EPS Miss Slightly Wider Than Expected; Stock Rises 2.74% Amid Strategic Review - Earnings Beat Streak - dars.gov.et
- 2026-07-01Aytu BioPharma Holds Steady Near $2.16 Amid Modest Gains – Key Levels in Focus - Factor Valuation - DonanımHaber
- 2026-06-27Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
- 2026-06-26Aytu BioPharma, Inc. Actuals & Estimates (NASDAQ:AYTU) - TradingView
- 2026-06-26AYTU Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25Aytu BioPharma (AYTU) ends Metadate CD license agreement with Lannett - Stock Titan
- 2026-06-25Price to sales forward of Aytu BioPharma, Inc. – NASDAQ:AYTU - TradingView
- 2026-06-25Aytu BioPharma Ends Metadate CD License With Lannett; Sell-Through Allowed After Mutual Termination - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.